Bacterial Meningitis Treatments

Find Bacterial Meningitis Treatments

Treatment Overview

Bacterial meningitis is a serious, life-threatening condition defined by the rapid inflammation of the membranes surrounding the brain and spinal cord. Symptoms like sudden, severe headache, stiff neck, and fever are frightening and require immediate attention. Because this is a medical emergency that can progress quickly, understanding the treatment is crucial, even though the care must begin immediately in a hospital setting.

Treatment is literally life-saving, aiming to prevent devastating complications such as brain damage, hearing loss, and death. Because the condition can worsen within hours, doctors initiate treatment instantly, even before lab tests confirm the specific type of bacteria causing the infection. While care is standardized involving powerful IV medications, the exact choice of drugs depends on the patient’s age, local resistance patterns, and any known allergies (Mayo Clinic, 2023).

Overview of treatment options for Bacterial Meningitis

The treatment for bacterial meningitis is aggressive, immediate, and dual-purpose: it must aggressively kill the invading bacteria and minimize the harmful inflammatory response they trigger. For this reason, treatment is always centered on a combination of strong antibiotics and anti-inflammatory medications.

Treatment is typically administered in the intensive care unit (ICU) of a hospital. Medications are given intravenously (IV) to ensure the highest possible concentration of the drug reaches the affected area in the central nervous system. Treatment cannot be delayed; unlike some conditions where waiting for test results is acceptable, medication must start immediately to improve outcomes. Supportive care, such as managing fever and fluid balance, accompanies the medical intervention.

Medications used for Bacterial Meningitis

The cornerstone of treatment is prompt administration of powerful, broad-spectrum antibiotics given through an IV. Since doctors start treatment immediately, they often use a combination of antibiotic classes to cover the widest range of possible bacteria.

Commonly used antibiotic classes include third-generation cephalosporins, such as ceftriaxone or cefotaxime. These are frequently combined with other drugs, like ampicillin, particularly in very young or elderly patients who are vulnerable to a specific bacteria called Listeria. Vancomycin is usually added to the regimen if doctors suspect the bacteria may be resistant to the primary antibiotics.

The second critical class of medication is corticosteroids, such as dexamethasone. This drug is given alongside the first dose of antibiotics. Corticosteroids are used to temper the severe inflammation caused when the antibiotics begin killing the bacteria. Patients can expect antibiotics to begin attacking the infection immediately, though neurological symptoms like confusion and headache may take several days to show noticeable improvement (Centers for Disease Control and Prevention, 2021).

How these medications work

Antibiotics are specifically selected because they possess the ability to cross the blood-brain barrier, a protective membrane that shields the brain from substances in the rest of the body. Once past this barrier, these drugs actively kill the bacteria by attacking vital structures. For instance, cephalosporins destroy the bacteria by preventing them from building a stable cell wall, causing them to burst and die.

Corticosteroids help reduce the immune system’s overreaction to the dying bacteria. When bacteria are killed, they release toxins that cause massive inflammation and swelling (edema) in the brain. The corticosteroids quickly reduce this swelling, which lowers pressure inside the skull. This protective action is critical for minimizing the risk of permanent complications like hearing loss and other neurological damage.

Side effects and safety considerations

Due to the potency and high doses required, bacterial meningitis medications pose safety risks. Antibiotics may cause common side effects like nausea, diarrhea, or allergic reactions, which are closely monitored. Drugs like Vancomycin necessitate regular blood testing to ensure an effective, yet non-kidney-damaging, dosage.

Corticosteroids, vital for brain protection, can temporarily cause elevated blood sugar, stomach irritation, or mood changes. The urgent, life-saving benefit outweighs these short-term side effects. Recovery can be prolonged; patients should report any new headaches, vision issues, or concentration difficulties to their doctor during follow-up (National Institute of Neurological Disorders and Stroke, 2023).

Since everyone’s experience with the condition and its treatments can vary, working closely with a qualified healthcare provider helps ensure safe and effective care.

References

  1. Centers for Disease Control and Prevention. https://www.cdc.gov
  2. Mayo Clinic. https://www.mayoclinic.org
  3. National Institute of Neurological Disorders and Stroke. https://www.ninds.nih.gov
  4. National Institutes of Health. https://www.nih.gov

Medications for Bacterial Meningitis

These are drugs that have been approved by the US Food and Drug Administration (FDA), meaning they have been determined to be safe and effective for use in Bacterial Meningitis.

Found 7 Approved Drugs for Bacterial Meningitis

Meropenem

Generic Name
Meropenem

Meropenem

Generic Name
Meropenem
Form: Injection
Method of administration: Intravenous
FDA approval date: October 14, 2011
Classification: Penem Antibacterial
Meropenem for injection (I.V.) is a penem antibacterial indicated for the treatment of: Complicated skin and skin structure infections (adult patients and pediatric patients 3 months of age and older only).

MethylPREDNISolone

Brand Names
Medrol, Solu-Medrol, Solu-Medrol MethylPREDNISolone

MethylPREDNISolone

Brand Names
Medrol, Solu-Medrol, Solu-Medrol MethylPREDNISolone
Form: Injection, Tablet
Method of administration: Oral, Intravenous, Intramuscular
FDA approval date: October 24, 1957
Classification: Corticosteroid
MEDROL Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler's syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement.

Minocycline

Brand Names
Amzeeq, Arestin, Emrosi, Minocin, ZILXI

Minocycline

Brand Names
Amzeeq, Arestin, Emrosi, Minocin, ZILXI
Form: Injection, Aerosol, Tablet, Powder, Capsule
Method of administration: Oral, Intravenous, Topical
FDA approval date: December 30, 1991
Classification: Tetracycline-class Drug
AMZEEQ is indicated for the topical treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in adults and pediatric patients 9 years of age and older. Limitations of Use This formulation of minocycline has not been evaluated in the treatment of infections. To reduce the development of drug-resistant bacteria as well as to maintain the effectiveness of other antibacterial drugs, AMZEEQ should be used only as indicated [ see Warnings and Precautions.

Kenalog

Brand Names
Bupivilog, Lidolog, Mlk F1, Mlk F3, Pro-C-Dure 6

Kenalog

Brand Names
Bupivilog, Lidolog, Mlk F1, Mlk F3, Pro-C-Dure 6
Form: Kit
Method of administration: Intra-articular, Epidural, Topical, Intramuscular, Infiltration
FDA approval date: January 16, 2014
Bupivacaine Hydrochloride Injection is indicated in adults for the production of local or regional anesthesia or analgesia for surgery, dental and oral surgery procedures, diagnostic and therapeutic procedures, and for obstetrical procedures. Specific concentrations and presentations of Bupivacaine Hydrochloride Injection are recommended for each type of block indicated to produce local or regional anesthesia or analgesia [see Dosage and Administration. Intramuscular Where oral therapy is not feasible, injectable corticosteroid therapy, including triamcinolone acetonide injectable suspension is indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis and systemic lupus erythematosus. Intra-Articular The intra-articular or soft tissue administration of triamcinolone acetonide injectable suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. For use as an first aid antiseptic pre-operative skin preperation.

Solu-Cortef

Generic Name
Solu-Cortef

Solu-Cortef

Generic Name
Solu-Cortef
Form: Injection
Method of administration: Intravenous, Intramuscular
FDA approval date: April 27, 1955
Classification: Corticosteroid
When oral therapy is not feasible, and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intravenous or intramuscular use of SOLU-CORTEF Sterile Powder is indicated as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), idiopathic thrombocytopenic purpura in adults (intravenous administration only; intramuscular administration is contraindicated), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous System: Cerebral edema associated with primary or metastatic brain tumor, or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, temporal arteritis, polymyositis, and systemic lupus erythematosus.
Showing 1-5 of 7
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances